COMMUNIQUÉ DE PRESSE
News
-
-
COMMUNIQUÉ DE PRESSE
Swiss Life Asset Management AG: Swiss Life REF (CH) ESG Swiss Properties: résultat semestriel net en hausse grâce à une plus grande efficience opérationnelle
Résultat semestriel net en hausse pour Swiss Life REF (CH) ESG Swiss Properties, grâce à une plus grande efficience opérationnelle. Détails dans le communiqué de presse -
COMMUNIQUÉ DE PRESSE
Sandoz marks 80 years of antibiotics with call for urgent political action to safeguard European medicine security
Sandoz celebrates 80 years of antibiotics production in Europe with urgent call for political action to ensure medicine security. Files landmark anti-dumping complaint -
COMMUNIQUÉ DE PRESSE
ASTA Energy Solutions AG reports strong Q1 2026 results, benefiting from accelerating market dynamics and strong commercial momentum
ASTA Energy Solutions AG reports strong Q1 2026 results, with net sales up 15.3% yoy, adjusted EBITDA increased by 68.6%, and net cash position at EUR 38.6 million. Company re-confirms guidance for 2026 -
-
COMMUNIQUÉ DE PRESSE
MRM Health rewarded a €2.6M VLAIO Research Grant to accelerate the development of novel therapeutics that redefine the treatment of immune-mediated inflammatory diseases
MRM Health rewarded a €2.6M VLAIO Research Grant to accelerate the development of novel therapeutics for immune-mediated inflammatory diseases, supported by cutting-edge microbiome research -
COMMUNIQUÉ DE PRESSE
Press Release: Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease
Sanofi's venglustat granted priority review by FDA for treating type 3 Gaucher disease. Potential first US therapy for neurological manifestations with target action date on November 25, 2026 -
COMMUNIQUÉ DE PRESSE
Communiqué de presse : Le venglustat de Sanofi a été accepté pour un examen prioritaire aux États-Unis afin de traiter la maladie de Gaucher de type 3
Sanofi's venglustat granted priority review by FDA for type 3 Gaucher disease treatment. Potential first US therapy for neurological manifestations. Action date set for Nov 25, 2026 -
COMMUNIQUÉ DE PRESSE
PURE Swiss Opportunity REF (PSO) – completes May 2026 capital increase with a solid result.
PURE Swiss Opportunity REF (PSO) successfully completes CHF 38.9 million capital increase, issuing 302,025 new units at CHF 128.80 per unit. Funds to be used for property acquisitions and debt-to-equity ratio reduction -
